ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.
ETFOptimize | HOME
Close Window
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

By: via GlobeNewswire

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows:

Wells Fargo 18th Annual Healthcare Conference Boston
 Kris Vaddi, Ph.D., Chief Executive Officer will participate in a Fireside chat on Wednesday, September 6, at 4:30 p.m. ET. The live webcast is available here. Dr. Vaddi and Laurent Chardonnet, Chief Financial Officer of Prelude, will host one-on-one meetings at the conference.

H. C. Wainwright 25th Annual Healthcare Investment Conference
 Dr. Vaddi and Jane Huang, MD, President and Chief Medical Officer will participate in a Fireside chat on Monday, September 11, at 1:30 p.m. ET. The live webcast is available here. Dr. Vaddi, along with Dr. Huang and Mr. Chardonnet will host one-on-one investor meetings at the conference.

Morgan Stanley 21st Annual Global Healthcare Conference
 On Tuesday, September 12, at 4:55 p.m. ET, Dr. Vaddi and Dr. Huang will participate in a Fireside chat. The live webcast is available here. Dr. Vaddi, Dr. Huang and Mr. Chardonnet will conduct one-on-one investor meetings at the conference.
  

About Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best/first-in-class proprietary small molecule compounds aimed at addressing specific pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, and a preclinical oral candidate targeting SMARCA2.

For more information, visit our website and follow us on LinkedIn and Twitter.

Investor Contact: 
Lindsey Trickett 
Vice President, Investor Relations 
240.543.7970 
ltrickett@preludetx.com

Media Contact: 
Helen Shik
Shik Communications
617.510.4373
helen@shikcommunications.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 
IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.